Medicure (TSE:MPH) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Medicure Inc. reported a decrease in total net revenue to $5.2 million in Q2 of 2024, down from $6.0 million in the same quarter the previous year, with significant drops in sales from its AGGRASTAT product due to increased generic competition. The company also experienced a net loss of $1.2 million, a stark contrast to the net income of $253,000 reported in Q2 of 2023.
For further insights into TSE:MPH stock, check out TipRanks’ Stock Analysis page.